Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Limited has announced an investor conference call to discuss the BLA filing update for its renal cancer imaging agent, TLX250-CDx. The call is scheduled for August 1, 2024, and aims to address Telix’s developments in diagnostic and therapeutic radiopharmaceuticals. Interested parties can register online to join the conference call and webcast.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
